Summary:
Tolerx, a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.
Tolerx, a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.
Investors 1
| Date | Name | Website |
| - | Rho Ventur... | rhoventure... |
Mentions in press and media 3
| Date | Title | Description |
| 07.10.2011 | Report: Tolerx Folds Its Tent, After $150M in Investment and a Failed Diabetes Drug Trial | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Tolerx, a once promising Boston biotech with a novel drug in development for diabetes, has reached the end of the road. The Cambridge, MA-based company is winding down operati... |
| 24.10.2007 | Life sciences briefing: Wednesday, Oct. 24, 2007 | Featured companies: Angstrom Medica, Asuragen, Aryx Therapeutics, HistoRx, MiMedx, Pioneer Surgical, Transfusion & Transplantation Technologies, Tolerx, Vivo Ventures UPDATED: Expanded Aryx and XDx items. UPDATE REDUX: Expanded Tolerx i... |
| 28.09.2007 | Can ToleRx Escape the Autoimmunity-Drug-Development Deathtrap? | Share Share on Facebook Share on Twitter LinkedIn Email Reprints “Like does not like like that is obnoxious.” Poet Marianne Moore wasn’t thinking of autoimmune diseases when she penned this line but it memorably captures the strife behind t... |